ABSTRACT
Purpose：A new simple and noninvasive stretch sensor (STR) has been developed to detect chest wall motion for respiratory rehabilitation. The purpose of this study was to investigate the validity of chest wall motion measurements obtained using the new stretch sensor.Methods：Twelve healthy male volunteers wore three different sensors (STR, respiratory inductance plethysmography [RIP], and flowmeter) while they performed the testing protocol, which included natural breathing (120 s), deep breathing (60 s), and polypneic (60 s) and apneic (30 s) conditions in the upright stance. The STR was implemented in two bands for the participant's chest and abdominal measurements. The ability of the three sensors to measure respiration and chest wall motion was analyzed.Results：The output signals from the STR showed significant correlation with the flow and RIP signals (r＝0.5-1.00, p＜0.05). The total number of breaths obtained from the STR signals showed no significant difference from the reference values obtained from the flowmeter signals (p＞0.05). The amplitude of the STR output signals changed significantly according to the respiratory maneuver used. Specifically, it increased from apnea, polypnea, and natural breathing to deep breathing (p＜0.05).Conclusion：The newly developed stretch sensor is capable of measuring chest wall motion in various breathing maneuvers in young men.
ABSTRACT
Opioids are potent analgesics mostly used for severe cancer and chronic noncancer pain. However, their efficacy and safety in acute noncancer pain are debatable. We describe the case of an 82-year-old male with severe back pain due to bacteremic Staphylococcus aureus spondylitis and paravertebral abscess. Pain in such cases is usually controlled by non-steroidal anti-inflammatory drugs (NSAIDs). However, this patient was administered morphine (oral, then intravenous; up to 23 mg/day) because acetaminophen and NSAIDs did not ameliorate pain. Considerable pain relief was achieved without toxicity, and the dose of morphine was tapered through 35 days. No symptoms of addiction or withdrawal were observed during or after this 35-day period. Thus, morphine appears to be safe and effective in the management of severe, acute noncancer pain in patients with bacterial spondylitis. Palliat Care Res 2010; 5(2): 327-331
ABSTRACT
It is well known that haloperidol is effective in the management of nausea and vomiting in cancer patients and that midazolam is used for inducing sedation in patients with delirium. Both the drugs are frequently used in a clinical setting, but there have been only few reports thus far on the concomitant administration of these 2 drugs. We report the case of a patient with massive ascites due to peritoneal carcinomatosis who had severe nausea and vomiting and went into a delirious state. This patient received a concomitant continuous infusion of haloperidol and midazolam for the management of these symptoms. Both haloperidol (up to 1.87mg/h) and midazolam (up to 1.87mg/h) were infused intravenously. For about 20 days, the nausea, vomiting and delirium were well under control without the development of any life threatening toxicities. Concomitant haloperidol and midazolam infusion was found to be a safe and effective therapy for the management of nausea and vomiting in the patient. Palliat Care Res 2009; 4(1): 312-316